BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer

To determine the effect of low dose azacitidine therapy on tumor infiltrating lymphocytes (TILs) in primary tumors from patients with high-risk early stage breast cancer, paired t-tests will be first used to compare TIL count in pre- and post-treatment specimens.

Trial Details

NCT ID
NCT04891068
Phase
PHASE2
Sponsor
University of Illinois Chicago
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Azacitidine
Locations (sample)
  • Chicago, Illinois, United States|41.85003,-87.65005

Key Eligibility Criteria

  • Age ≥ 18 years of age at time of consent
  • ECOG 0, 1, or 2
  • Histologically confirmed invasive breast carcinoma documented by biopsy. AJCC 8th edition clinical stage T1a-T3/N0-N1/M0 by physical exam or radiol…
  • Disease characteristics I. TNBC (Less than or equal to 10% of tumor cells staining for ER and for PR by immunohistochemistry (IHC). HER2-negative, …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →